Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
HBIO Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 12, 2026
Report Source: 2026 1st Quarter Report
Harvard Bioscience Inc. Stock Analysis HBIO
United States Health Care Nano Cap Report: Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2013-10-21. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Read More Harvard Bioscience Inc (HBIO) Chart
Key Statistics of Harvard Bioscience Inc (HBIO)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$5.97Volume
8972.00P/E Ratio (TTM)
-52 Week Range
Market Cap
24.90MAvg. Volume
24.86KDividend Yield
-Financial Metrics & Statements of Harvard Bioscience Inc (HBIO)
FAQ's for Harvard Bioscience Inc (HBIO)
- According to Musaffa’s Shariah screening methodology, Harvard Bioscience Inc (HBIO) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Harvard Bioscience Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Harvard Bioscience Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Harvard Bioscience Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Harvard Bioscience Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Harvard Bioscience Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.